基因型指导抗血小板治疗:JACC本周综述
综述探讨药物基因组学指导抗血小板治疗的潜力,指出CYP2C19等位基因变异可解释抗血小板药物反应差异,支持对双联抗血小板治疗指征患者进行基因型指导。替格瑞洛/普拉格雷治疗者基因型指导降阶可降低出血风险,氯吡格雷治疗者升阶可预防缺血事件,但临床实施仍有限。
要点
- CYP2C19等位基因变异是指导双联抗血小板治疗的主要证据基础。
- 替格瑞洛/普拉格雷治疗者基因型指导降阶策略可降低出血风险。
- 氯吡格雷治疗者基因型指导升阶策略可能预防缺血事件。
核心结论
- 基因型指导抗血小板治疗有潜力优化药物选择和剂量,但临床实施仍少。
研究设计与样本
- JACC本周综述,总结药物基因组学对抗血小板药物反应个体差异的影响及基因型指导策略的证据。
主要发现
- 抗血小板药物疗效和安全性存在个体差异,部分与药物代谢酶基因变异有关。
- 多数证据支持基于CYP2C19等位基因变异指导双联抗血小板治疗。
- 替格瑞洛或普拉格雷治疗者基因型指导降阶可降低出血风险,氯吡格雷治疗者升阶可预防缺血事件。
临床怎么用
- 对双联抗血小板治疗指征患者可考虑CYP2C19基因型指导选择或调整抗血小板药物。
局限性
- 基因型指导策略临床实施有限,需新技术和新证据克服障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events during treatment. This interindividual variability can be a result of genetic variants in enzymes that play a role in drug metabolism. The field of pharmacogenomics explores the influence of these genetic variants on an individual's drug response. Tailoring antiplatelet treatment based on genetic variants can potentially result in optimized dosing or a change in drug selection. Most evidence supports guiding therapy based on the CYP2C19 allelic variants in patients with an indication for dual antiplatelet therapy. In ticagrelor-treated or prasugrel-treated patients, a genotype-guided de-escalation strategy can reduce bleeding risk, whereas in patients treated with clopidogrel, an escalation strategy may prevent ischemic events. Although the clinical results are promising, few hospitals have implemented these strategies. New results, technological advancements, and growing experience may potentially overcome current barriers for implementation in the future.
引用
- van den Broek WWA, Ingraham BS, Pereira NL, et al. Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week. J Am Coll Cardiol. 2024. PMID: 39260933. doi:10.1016/j.jacc.2024.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。